Posted by Michael Wonder on 19 Mar 2024
FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
19 March 2024 - Today, the FDA granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Efficacy was evaluated in PhALLCON, a randomised, active-controlled, multi-centre, open-label trial of 245 adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia.
